Global Digital PCR and Real-Time PCR Market Growth Driven by Increasing Cases of Infectious Diseases
|
By LabMedica International staff writers Posted on 20 Apr 2021 |

Illustration
Increasing cases of infectious diseases, rising geriatric population and growing number of genetic disorders will propel the growth of the global digital PCR and real-time PCR market over the next decade. Additionally, PCR advances, fulfillment of the human genome project, and expanding R&D will increase the utilization of biomarker profiling for sickness diagnostics, thus further driving market growth.
These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.
The interest in genomic examination strategies has increased consistently during the most recent decade due to their expanding use in the analysis of major illnesses (like HIV, tuberculosis, intestinal sickness, and hepatitis) and hereditary problems (like malignancy). The development in the commonness of target illnesses worldwide, combined with the demonstrated adequacy of qPCR and dPCR examination in the determination and assessment of sickness-causing microorganisms, will drive the utilization of clinical indicative tests (including qPCR and dPCR investigation) and support market development.
Geographically, North America is expected to dominate the global digital PCR and real-time PCR market, followed by Europe. The development of the North American qPCR and dPCR market will be driven by an expanded selection of innovative and novel genomic examination items (including progressed qPCR and dPCR items), accessibility to R&D financing for genomic research, growing utilization of PCR methods in clinical diagnostics and criminology, and early commercialization of qPCR/dPCR items.
Related Links:
TMR Research
These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.
The interest in genomic examination strategies has increased consistently during the most recent decade due to their expanding use in the analysis of major illnesses (like HIV, tuberculosis, intestinal sickness, and hepatitis) and hereditary problems (like malignancy). The development in the commonness of target illnesses worldwide, combined with the demonstrated adequacy of qPCR and dPCR examination in the determination and assessment of sickness-causing microorganisms, will drive the utilization of clinical indicative tests (including qPCR and dPCR investigation) and support market development.
Geographically, North America is expected to dominate the global digital PCR and real-time PCR market, followed by Europe. The development of the North American qPCR and dPCR market will be driven by an expanded selection of innovative and novel genomic examination items (including progressed qPCR and dPCR items), accessibility to R&D financing for genomic research, growing utilization of PCR methods in clinical diagnostics and criminology, and early commercialization of qPCR/dPCR items.
Related Links:
TMR Research
Latest Industry News
- Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
- Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
- Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
- Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio
- Agilent Strengthens Pathology Capabilities Through Biocare Acquisition
- Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
- Project Aims to Develop First Single-Cell Assay for ADC Therapies
- Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
- Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing
- Partnership Aims to Improve Transplant Monitoring Across Care Continuum
- QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
- Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
- Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
- Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
- Open-Source Consortium Aims to Standardize Digital Pathology Workflows
- Diazyme Laboratories Acquires Carolina Liquid Chemistries
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read moreMolecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read morePathology
view channel
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
Colorectal cancer remains a leading cause of cancer mortality, and many patients relapse despite apparently successful surgery and chemotherapy. Detecting minimal disease that persists after treatment... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more








